Mark J. Holdbrook is V.P., Clinical Affairs of Tarsus Pharmaceuticals, Inc.. Currently has a direct ownership of 3,191 shares of TARS, which is worth approximately $141,967. The most recent transaction as insider was on Mar 20, 2023, when has been sold 198 shares (Common Stock) at a price of $12.61 per share, resulting in proceeds of $2,496. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.19K
0% 3M change
0% 12M change
Total Value Held $141,967

Mark J. Holdbrook Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 20 2023
SELL
Open market or private sale
$2,496 $12.61 p/Share
198 Reduced 5.84%
3,191 Common Stock
Mar 17 2023
SELL
Open market or private sale
$2,496 $13.28 p/Share
188 Reduced 5.26%
3,389 Common Stock
Mar 16 2023
SELL
Open market or private sale
$2,511 $13.43 p/Share
187 Reduced 4.97%
3,577 Common Stock
Mar 15 2023
BUY
Exercise of conversion of derivative security
-
2,653 Added 41.34%
3,764 Common Stock
MJH

Mark J. Holdbrook

V.P., Clinical Affairs
Irvine, CA

Track Institutional and Insider Activities on TARS

Follow Tarsus Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TARS shares.

Notify only if

Insider Trading

Get notified when an Tarsus Pharmaceuticals, Inc. insider buys or sells TARS shares.

Notify only if

News

Receive news related to Tarsus Pharmaceuticals, Inc.

Track Activities on TARS